These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 11965603

  • 1. Somatostatin receptor imaging.
    Kwekkeboom DJ, Krenning EP.
    Semin Nucl Med; 2002 Apr; 32(2):84-91. PubMed ID: 11965603
    [Abstract] [Full Text] [Related]

  • 2. Peptide receptor imaging and therapy.
    Kwekkeboom D, Krenning EP, de Jong M.
    J Nucl Med; 2000 Oct; 41(10):1704-13. PubMed ID: 11038002
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness analysis of somatostatin receptor scintigraphy.
    Kwekkeboom DJ, Lamberts SW, Habbema JD, Krenning EP.
    J Nucl Med; 1996 Jun; 37(6):886-92. PubMed ID: 8683305
    [Abstract] [Full Text] [Related]

  • 4. Radiolabeled somatostatin analog scintigraphy in oncology and immune diseases: an overview.
    Kwekkeboom DJ, Krenning EP.
    Eur Radiol; 1997 Jun; 7(7):1103-9. PubMed ID: 9265684
    [Abstract] [Full Text] [Related]

  • 5. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan).
    Olsen JO, Pozderac RV, Hinkle G, Hill T, O'Dorisio TM, Schirmer WJ, Ellison EC, O'Dorisio MS.
    Semin Nucl Med; 1995 Jul; 25(3):251-61. PubMed ID: 7570044
    [Abstract] [Full Text] [Related]

  • 6. Gastroenteropancreatic tumor imaging with somatostatin receptor scintigraphy.
    Wiedenmann B, Bäder HM, Scherubl H, Fett U, Zimmer T, Hamm B, Koppenhagen K, Riecken EO.
    Semin Oncol; 1994 Oct; 21(5 Suppl 13):29-32. PubMed ID: 7992077
    [No Abstract] [Full Text] [Related]

  • 7. [Preliminary results on the use of scintigraphy with radiolabelled octreotide as diagnostic method in neuroendocrine and nonendocrine neoplasms of the lung].
    Oliaro A, Filosso PL, Bellò M, Casadio C, Muni A, Angusti T, Masaneo I, Bisi G, Maggi G.
    Minerva Chir; 1997 Nov; 52(11):1335-8. PubMed ID: 9489331
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Role of somatostatin analogs in the treatment of neuroendocrine tumours].
    Cuccurullo V, Cascini GL, Rambaldi PF, Mansi L.
    Minerva Endocrinol; 2001 Sep; 26(3):135-43. PubMed ID: 11753236
    [Abstract] [Full Text] [Related]

  • 11. 111In-octreotide scintigraphy in small cell lung cancer.
    Semprebene A, Ferraironi A, Franciotti G, Venturo I, Giunta S, Lopez M, Maini CL.
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):108-10. PubMed ID: 9002764
    [Abstract] [Full Text] [Related]

  • 12. Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results.
    Krenning EP, Kwekkeboom DJ, Oei HY, de Jong RJ, Dop FJ, Reubi JC, Lamberts SW.
    Ann N Y Acad Sci; 1994 Sep 15; 733():416-24. PubMed ID: 7978890
    [No Abstract] [Full Text] [Related]

  • 13. Somatostatin receptors and breast cancer.
    van Eijck CH, Kwekkeboom DJ, Krenning EP.
    Q J Nucl Med; 1998 Mar 15; 42(1):18-25. PubMed ID: 9646641
    [Abstract] [Full Text] [Related]

  • 14. [The scintigraphy of somatostatin receptors in gastroenteropancreatic neuroendocrine tumors].
    Chiti A, Spinelli A, Bombardieri E.
    Radiol Med; 1997 Oct 15; 94(4):362-70. PubMed ID: 9465244
    [No Abstract] [Full Text] [Related]

  • 15. Radiolabeled octreotide for the demonstration of somatostatin receptors in malignant lymphoma and lymphadenopathy.
    Lipp RW, Silly H, Ranner G, Dobnig H, Passath A, Leb G, Krejs GJ.
    J Nucl Med; 1995 Jan 15; 36(1):13-8. PubMed ID: 7799065
    [Abstract] [Full Text] [Related]

  • 16. Somatostatin receptor scintigraphy in brain tumors and pituitary tumors: first experiences.
    Scheidhauer K, Hildebrandt G, Luyken C, Schomäcker K, Klug N, Schicha H.
    Horm Metab Res Suppl; 1993 Jan 15; 27():59-62. PubMed ID: 8330874
    [Abstract] [Full Text] [Related]

  • 17. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors.
    Janson ET, Westlin JE, Ohrvall U, Oberg K, Lukinius A.
    J Nucl Med; 2000 Sep 15; 41(9):1514-8. PubMed ID: 10994731
    [Abstract] [Full Text] [Related]

  • 18. Use of an isotopic somatostatin receptor probe to image gut endocrine tumors.
    Modlin IM, Cornelius E, Lawton GP.
    Arch Surg; 1995 Apr 15; 130(4):367-73; discussion 373-4. PubMed ID: 7710334
    [Abstract] [Full Text] [Related]

  • 19. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy.
    Otte A, Jermann E, Behe M, Goetze M, Bucher HC, Roser HW, Heppeler A, Mueller-Brand J, Maecke HR.
    Eur J Nucl Med; 1997 Jul 15; 24(7):792-5. PubMed ID: 9211767
    [Abstract] [Full Text] [Related]

  • 20. Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours.
    Slooter GD, Mearadji A, Breeman WA, Marquet RL, de Jong M, Krenning EP, van Eijck CH.
    Br J Surg; 2001 Jan 15; 88(1):31-40. PubMed ID: 11136306
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.